… ) human papillomavirus (HPV) genotypes cause virtually all cervical cancer and its immediate
precursor lesions worldwide. Prophylactic vaccines against human papillomavirus (HPV) …

… association between HPV vaccine and a range of such conditions. Whilst this reassuring
safety profile affirms the positive risk benefit of vaccination, as HPV vaccine use expands into …

While two prophylactic HPV vaccines have been proven notably efficacious in clinical trials,
the effectiveness of these vaccines at the population level remains to be evaluated. To lay …

… Population-level impact and herd effects following the introduction of human papillomavirus
vaccination … Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV …

… Vaccines approved for use by the regulatory authorities have … the usage of the vaccine,
such as in the UK where a girl from Coventry in 2009 died following a cervical cancer vaccination …

… ’s (WHO) recommendations on the use of human papillomavirus (HPV) vaccines excerpted
from the WHO position paper on Human papillomavirus vaccines: WHO position paper, May …

… the first human papillomavirus (HPV) vaccine was introduced. These vaccines have received
… The use of social media to promote pro-HPV vaccination messages can be one strategy to …

… the use of preventive HPV vaccines in countries that carry the majority of the cervical cancer
burden. In addition, progression of therapeutic HPV vaccines … of HPV vaccines continues, we …

… the patterns of use we observe continue as the vaccine has been on the market for a
more extended period. In addition, as data become available, vaccine dose completion rates …

… of human papillomavirus (HPV). Two recently developed prophylactic cervical cancer vaccines…
using the bivalent vaccine in their vaccine programmes, whilst others use the quadrivalent …